CompuMed, Inc. (CMPD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CompuMed, Inc. (CMPD) with AI Score 60/100 (Hold). CompuMed, Inc. is a telemedicine solutions company providing clinical care services through cloud-based technology and integrated medical devices. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026CompuMed, Inc. (CMPD) Healthcare & Pipeline Overview
CompuMed, Inc. delivers telemedicine solutions, specializing in telecardiology and teleradiology services. The company connects global medical facilities with U.S. Board-Certified specialists through its cloud-based platform and integrated medical devices, serving organ procurement, rural healthcare, and correctional healthcare industries, while navigating the competitive healthcare information services landscape.
Investment Thesis
CompuMed, Inc. operates in the growing telemedicine market, offering specialized services in telecardiology and teleradiology. The company's cloud-based platform and integrated medical devices provide access to specialists, addressing the increasing demand for remote healthcare solutions. With a market capitalization of $0.01 billion, CompuMed faces challenges, indicated by a negative P/E ratio of -56.36 and a negative profit margin of -1.8%. However, its gross margin of 46.8% suggests potential for profitability with improved operational efficiency. Key growth catalysts include expanding its mobile ECG and ultrasound solutions and penetrating underserved markets such as rural healthcare and correctional facilities. The company's OsteoGram software also presents an opportunity for growth in osteoporosis screening. Investors should monitor the company's ability to scale its operations and achieve profitability in the competitive telemedicine landscape.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01 billion reflects its small size within the telemedicine industry.
- P/E ratio of -56.36 indicates the company is currently not profitable.
- Profit Margin of -1.8% shows the company is operating at a slight loss.
- Gross Margin of 46.8% suggests strong potential for profitability if operational costs are managed effectively.
- Beta of -0.29 indicates the stock is less volatile than the market.
Competitors & Peers
Strengths
- Specialized expertise in telecardiology and teleradiology.
- Cloud-based technology platform for efficient remote consultations.
- Established network of U.S. Board-Certified specialists.
- Proprietary OsteoGram software for osteoporosis screening.
Weaknesses
- Small market capitalization and limited financial resources.
- Negative P/E ratio and profit margin.
- High dependence on a small number of key customers.
- Limited brand recognition compared to larger competitors.
Catalysts
- Upcoming: Expansion of mobile ECG and ultrasound solutions into new geographic markets.
- Ongoing: Strategic partnerships with rural healthcare facilities to provide telemedicine services.
- Ongoing: Development and marketing of enhanced OsteoGram software for osteoporosis screening.
- Upcoming: Potential regulatory changes favoring telemedicine reimbursement.
- Ongoing: Increasing adoption of telemedicine due to rising healthcare costs and aging populations.
Risks
- Potential: Intense competition from larger telemedicine providers with greater financial resources.
- Potential: Cybersecurity breaches compromising patient data and disrupting services.
- Ongoing: Limited financial resources and negative profitability impacting growth prospects.
- Potential: Economic downturn reducing healthcare spending and demand for telemedicine services.
- Ongoing: Regulatory hurdles and compliance requirements in different geographic markets.
Growth Opportunities
- Expansion of Mobile ECG and Ultrasound Solutions: CompuMed can capitalize on the growing demand for mobile healthcare solutions by expanding its mobile ECG and ultrasound services. The market for mobile medical devices is projected to reach substantial figures by 2028, driven by increased patient convenience and remote monitoring capabilities. By offering immediate access to board-certified specialists through mobile devices, CompuMed can attract a larger customer base and increase its revenue streams. This expansion requires investment in technology and marketing to reach a wider audience.
- Penetration of Underserved Markets: CompuMed has the opportunity to penetrate underserved markets such as rural healthcare facilities and correctional institutions. These markets often lack access to specialized medical expertise, creating a demand for telemedicine solutions. By partnering with rural hospitals and correctional facilities, CompuMed can provide telecardiology and teleradiology services to patients who would otherwise not have access to them. This expansion requires building relationships with key stakeholders and tailoring its services to meet the specific needs of these markets.
- Growth of OsteoGram Software: CompuMed's OsteoGram software, which aids in osteoporosis screening, diagnosis, and therapy monitoring, presents a significant growth opportunity. As the global population ages, the prevalence of osteoporosis is expected to increase, driving demand for diagnostic tools. By enhancing the capabilities of OsteoGram and marketing it to healthcare providers, CompuMed can capture a larger share of the osteoporosis screening market. This requires ongoing research and development to improve the software's accuracy and user-friendliness.
- Strategic Partnerships with Organ Procurement Organizations: CompuMed serves organ procurement organizations (OPOs), offering telemedicine solutions that can improve the efficiency and effectiveness of organ donation processes. By forming strategic partnerships with more OPOs, CompuMed can expand its reach and increase its revenue. Telemedicine can facilitate remote consultations and assessments, ensuring that organs are properly evaluated and allocated in a timely manner. This requires demonstrating the value of its services to OPOs and building strong relationships with key decision-makers.
- International Expansion: CompuMed has the potential to expand its services internationally, particularly in regions with limited access to specialized medical expertise. By targeting countries with developing healthcare systems, CompuMed can provide telecardiology and teleradiology services to a broader patient population. This expansion requires understanding the regulatory landscape and cultural nuances of each target market. It also requires building a network of local partners to facilitate service delivery and ensure compliance with local laws.
Opportunities
- Expansion into underserved markets such as rural healthcare and correctional facilities.
- Growth of mobile ECG and ultrasound solutions.
- Increased adoption of telemedicine due to COVID-19 pandemic.
- Strategic partnerships with organ procurement organizations.
Threats
- Intense competition from larger telemedicine providers.
- Regulatory changes affecting telemedicine reimbursement.
- Cybersecurity risks associated with cloud-based technology.
- Economic downturn impacting healthcare spending.
Competitive Advantages
- Specialized Expertise: Focus on telecardiology and teleradiology provides a niche advantage.
- Cloud-Based Technology: Proprietary platform enables efficient and secure remote consultations.
- Established Network: Existing relationships with U.S. Board-Certified specialists.
- OsteoGram Software: Unique software offering for osteoporosis screening and monitoring.
About CMPD
Founded in 1973 and headquartered in Los Angeles, California, CompuMed, Inc. has evolved into an enterprise telemedicine solutions company. It provides clinical care services to patients and medical facilities, leveraging cloud-based technology to offer real-time access to U.S. Board-Certified specialists. CompuMed's core offerings include telecardiology and teleradiology services, enabling remote consultations and diagnostic interpretations. The company's suite of services covers a wide range of diagnostic exams, including electrocardiograms (ECG), echocardiograms, vascular studies, Holter monitoring, nuclear imaging, and video consultations. These services cater to both pediatric and adult patients. CompuMed also provides reading, transcription, reporting, and storage solutions for medical images in areas such as Vscan, X-ray, ultrasound, mammography, computed tomography, and magnetic resonance imaging. A key product is OsteoGram, a software that integrates with standard or digital X-ray equipment to aid in osteoporosis screening, diagnosis, and therapy monitoring. CompuMed extends its reach through mobile ECG and ultrasound solutions, ensuring patients have immediate access to specialists. The company serves diverse sectors, including organ procurement organizations, rural healthcare facilities, and correctional healthcare institutions.
What They Do
- Provides telecardiology services, offering remote cardiac consultations and diagnostic interpretations.
- Offers teleradiology services, enabling remote radiological image analysis and reporting.
- Develops and markets OsteoGram software for osteoporosis screening and monitoring.
- Provides mobile ECG and ultrasound solutions for immediate access to specialists.
- Offers enterprise telemedicine solutions for medical facilities.
- Connects patients with U.S. Board-Certified specialists through cloud-based technology.
- Provides reading, transcription, reporting, and storage solutions for medical images.
Business Model
- Fee-for-service model: Charging medical facilities and healthcare providers for telecardiology and teleradiology consultations.
- Software licensing: Generating revenue from licensing the OsteoGram software to healthcare providers.
- Subscription-based services: Offering subscription packages for ongoing access to telemedicine services and support.
- Medical device sales: Selling ECG devices and ultrasound equipment to medical facilities and patients.
Industry Context
CompuMed, Inc. operates within the healthcare information services industry, a sector experiencing growth driven by the increasing adoption of telemedicine and remote patient monitoring. The global telemedicine market is projected to reach significant growth in the coming years, fueled by factors such as aging populations, rising healthcare costs, and advancements in technology. CompuMed competes with other telemedicine providers, including CLABF (Cloudbreak Health), CNGGF (CloudMD Software & Services Inc.), CPMV (CPM Medical Consultants), DOGP (Dogness International Corporation), and FNAM (Fnampt AG), as well as larger healthcare technology companies. The company's focus on specialized services like telecardiology and teleradiology positions it within a niche segment of the broader telemedicine market.
Key Customers
- Hospitals and medical centers seeking to expand their service offerings.
- Rural healthcare facilities lacking on-site specialists.
- Organ procurement organizations requiring efficient remote assessments.
- Correctional healthcare facilities providing medical care to inmates.
Financials
Chart & Info
CompuMed, Inc. (CMPD) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMPD.
Price Targets
Wall Street price target analysis for CMPD.
MoonshotScore
What does this score mean?
The MoonshotScore rates CMPD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lee Keddie
CEO
Lee Keddie serves as the CEO of CompuMed, Inc., leading a team of 8 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided source data. Therefore, a comprehensive background profile cannot be constructed at this time. Further research would be required to ascertain his specific qualifications and experience prior to joining CompuMed, Inc.
Track Record: Due to the limited information available in the provided source data, it is not possible to assess Lee Keddie's track record at CompuMed, Inc. Specific achievements, strategic decisions, and company milestones under his leadership cannot be determined without additional data. Further research is needed to evaluate his performance and contributions to the company's growth and development.
CMPD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CompuMed, Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to limited regulatory oversight and may not provide regular financial disclosures. Compared to NYSE or NASDAQ listings, OTC Other stocks typically have lower trading volumes, wider bid-ask spreads, and higher price volatility. Investors should be aware of the increased risks associated with investing in companies on this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and financial disclosure requirements.
- Low trading volume and liquidity.
- Wider bid-ask spreads and higher price volatility.
- Potential for fraud or manipulation.
- Increased risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's cash flow and debt levels.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in business since 1973.
- Offers specialized telemedicine services in telecardiology and teleradiology.
- Serves organ procurement organizations, rural healthcare, and correctional healthcare industries.
- Has a cloud-based technology platform and integrated medical devices.
Common Questions About CMPD
What does CompuMed, Inc. do?
CompuMed, Inc. is a telemedicine solutions company that provides clinical care services to patients and medical facilities. It specializes in telecardiology and teleradiology, offering remote consultations and diagnostic interpretations through its cloud-based platform and integrated medical devices. The company connects patients with U.S. Board-Certified specialists, enabling access to specialized medical expertise in underserved areas. CompuMed also provides OsteoGram software for osteoporosis screening and monitoring, as well as mobile ECG and ultrasound solutions for immediate access to specialists.
What do analysts say about CMPD stock?
AI analysis is currently pending for CMPD, and therefore, a summary of analyst consensus is not available at this time. Key valuation metrics such as revenue growth projections, earnings estimates, and price targets are currently unavailable. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Further research is needed to assess the company's growth potential and financial performance.
What are the main risks for CMPD?
CompuMed, Inc. faces several risks, including intense competition from larger telemedicine providers, cybersecurity threats to its cloud-based platform, limited financial resources, and potential regulatory changes affecting telemedicine reimbursement. The company's negative profitability and small market capitalization also pose challenges to its growth prospects. An economic downturn could reduce healthcare spending and demand for telemedicine services, further impacting the company's financial performance. Investors should carefully consider these risks before investing in CMPD.
What are the key factors to evaluate for CMPD?
CompuMed, Inc. (CMPD) currently holds an AI score of 60/100, indicating moderate score. Key strength: Specialized expertise in telecardiology and teleradiology.. Primary risk to monitor: Potential: Intense competition from larger telemedicine providers with greater financial resources.. This is not financial advice.
How frequently does CMPD data refresh on this page?
CMPD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CMPD's recent stock price performance?
Recent price movement in CompuMed, Inc. (CMPD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in telecardiology and teleradiology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CMPD overvalued or undervalued right now?
Determining whether CompuMed, Inc. (CMPD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CMPD?
Before investing in CompuMed, Inc. (CMPD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC Other stocks are inherently more risky and require thorough due diligence.